im19 car-t cells
Cell therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 4, 2020 (NCT04440436)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06513429 | N/A | Jul 30, 2024 | Peking University |
| NCT05480501 | Early Phase 1 (Phase 1) | Jul 11, 2022 | Beijing Immunochina Medical Science & Technology Co., Ltd., China Medical University |
| NCT05309213 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2022 | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University |
| NCT05155215 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University |
| NCT04440436 | Phase 1/Phase 2 (Phase 2) | Jun 4, 2020 | Beijing Immunochina Medical Science & Technology Co., Ltd., Chinese Academy of Medical Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immunochina Medical Science & Technology Co., Ltd. | For profit | 4 | 4 | 2 | 2020 |
| Peking University | Academic/Hospital | 3 | 1 | 2 | 2021 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1